# **Preventive Health Care**

Federal Bureau of Prisons Clinical Practice Guidelines

April 2009

Clinical guidelines are made available to the public for informational purposes only. The Federal Bureau of Prisons (BOP) does not warrant these guidelines for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient specific. Consult the BOP Clinical Practice Guidelines Web page to determine the date of the most recent update to this document: http://www.bop.gov/news/medresources.jsp

## What's New in the Document?

Revisions to the April 2007 version of the BOP Clinical Practice Guidelines for Preventive Health Care are outlined below. These changes are primarily based on updated guidance from the U.S. Preventive Services Task Force (USPSTF).

- <u>**HIV screening:**</u> Routinely encourage HIV testing for all sentenced inmates who have not been previously tested in the BOP.
- <u>Colorectal cancer screening</u>: BOP and USPSTF recommend fecal occult blood testing (FOBT) for average risk persons, beginning at age 50. It is emphasized that 3 FOBTs annually are necessary to achieve adequate sensitivity for cancer screening. Routine screening for colorectal cancer screening should cease at age 75. Updated American Cancer Society/American Gastroenterological Association guidelines for screening persons who are at increased risk for colorectal cancer are included in the current document.
- **Diabetes screening:** The USPSTF has concluded that there is only one group of asymptomatic, individuals for whom routine diabetes screening is warranted: those with a blood pressure greater than 135/80 (treated or untreated). Screening should also be performed as clinically warranted, including for hyperlipidemia, cardiovascular disease, peripheral vascular disease, history of gestational diabetes or history of polycystic ovary disease. Screen with a fasting serum glucose (confirming with a fasting plasma glucose test for values that are borderline high).
- <u>**Blood pressure screening:**</u> Inmates with borderline blood pressure elevations (systolic 120–139; diastolic 80–90) should be screened annually.
- <u>Screening for lipid disorders</u>: Routine screening of average-risk women is no longer recommended.
- <u>Aspirin for CVD prevention</u>: Risk-based guidance is provided on whether or not to recommend aspirin, based on the risk of CVD in men and the risk of stroke in women, as compared against the risk of gastrointestinal hemorrhage. For men, calculate the 10-year risk of CVD every 5 years, beginning at age 45. For women, calculate the 10-year risk of stroke every 5 years, beginning at age 55. Links to risk calculators are provided in this document.

|                 | Men<br>r CHD risk | Wor<br>10-year s | nen<br>troke risk |
|-----------------|-------------------|------------------|-------------------|
| Age 45–59 years | <u>&gt;4%</u>     | Age 55–59 years  | <u>&gt;</u> 3%    |
| Age 60–69 years | <u>&gt;9%</u>     | Age 60–69 years  | <u>&gt;8%</u>     |
| Age 70–79 years | >12%              | Age 70–79 years  | >11%              |

#### Risk Level at which Prevented CVD Events ("Benefit") Exceed GI Harms

- <u>Pneumococcal vaccine</u> is no longer recommended routinely for Native Americans/Alaskan Natives. Pneumococcal vaccine is now recommended for inmates with asthma, cerebrospinal fluid leaks, those with chronic alcoholism, and those who are long-term care residents. For inmates with newly diagnosed HIV-infection, pneumococcal vaccine should be administered as close as possible to the time of diagnosis.
- <u>Meningococcal vaccine</u> is recommended for inmates with asplenia, i.e., sickle cell disease.

## **Table of Contents**

| 1. | <u>Purpose</u>                            |   |
|----|---|---|
| 2. | Preventive Health Care Overview           |   |
| 3. | Preventive Health Care Scope of Services  |   |
|    | Intake                                    |   |
|    | Prevention Baseline Visit                 |   |
|    | Prevention Periodic Visits                |   |
| 4. | Preventive Health Care Delivery           | r |
| 5. | Preventive Health Care Program Evaluation | r |
|    |   |   |

### Appendices

| Appendix 1. | Preventive Health Care - Intake Parameters                     | 5 |
|-------------|--|---|
| Appendix 2. | Preventive Health Care Scope of Services for Sentenced Inmates | 6 |
| Appendix 3. | Preventive Health Care Guidelines by Disease State             | 8 |

| Infectious Disease Screening                         |
|--|
| Hepatitis B Viral Infection                          |
| Hepatitis C Viral Infection                          |
| <u>HIV-1, HIV-2</u>                                  |
| Sexually Transmitted Diseases (Chlamydia & Syphilis) |
| Tuberculosis   |
|  |

| Cancer Screening |  | . 10 |
|------------------|--|------|
|------------------|--|------|

Breast Cancer Cervical Cancer Ovarian Cancer Prostate Cancer Colorectal Cancer

| <b>Chronic Diseases</b> | s/Lifestyle                           | 13 |
|-------------------------|---------------------------------------|----|
| At                      | odominal Aortic Aneurysm              |    |
| As                      | pirin for Cardiovascular Disease Risk |    |
| Di                      | abetes Mellitus                       |    |
| Hy                      | pertension                            |    |
| Li                      | pid Disorders                         |    |
| Ob                      | pesity                                |    |
| Os                      | iteoporosis                           |    |
| Su                      | bstance Abuse                         |    |

| Sensory Scree | ening                        |
|---------------|------------------------------|
|               | Vision                       |
|               | Hearing                      |
| Immunizatio   | ns                           |
|               | Hepatitis A                  |
|               | Hepatitis B                  |
|               | Influenza                    |
|               | Measles-Mumps-Rubella        |
|               | Meningococcal                |
|               | Pneumococcal                 |
|               | Tetanus-Diphtheria-Pertussis |
|               | i                            |
|               |                              |

| Appendix 4a. | Inmate Fact Sheet - Preventive Health Program for Women |
|--------------|---|
| Appendix 4b. | Inmate Fact Sheet - Preventive Health Program for Men   |
| Appendix 5.  | Staff Roles for Preventive Health Care Delivery         |
| Appendix 6.  | Selected Preventive Health Care References              |

## 1. Purpose

The Federal Bureau of Prisons (BOP) clinical practice guidelines for preventive health care outline health maintenance recommendations for federal inmates.

These preventive health guidelines *do not cover* diagnostic testing or medical treatments that might be indicated by a patient's signs and symptoms. These guidelines also *do not preclude* patient-specific screenings based on medical histories and evaluations.

## 2. Preventive Health Care Overview

Based on the recommendations of the U.S. Preventive Services Task Force (USPSTF), the BOP defines a scope of preventive health care services for inmates that incorporates targeted patient counseling and immunizations, as well as screening for infectious diseases, cancer, and chronic diseases. The BOP preventive health care program deviates from USPSTF recommendations only when the risk characteristics of the BOP inmate population suggest an alternative approach. The BOP preventive health care program includes the following components:

- A health care delivery system that uses a multi-disciplinary team approach, with specific duties assigned to each team member.
- An emphasis on the inmate's responsibility for improving his or her own health status and seeking preventive services.
- Prioritization of inmates who are at high risk for specific health problems.
- Recognition that routine physical examinations are not a recommended component of a preventive health care program.

## 3. Preventive Health Care Scope of Services

### Intake

Newly incarcerated inmates are screened for conditions that warrant prompt intervention: contagious diseases, active substance abuse, chronic diseases, and mental illness. Intake screening and prevention parameters are outlined in <u>Appendix 1</u> (Preventive Health Care - Intake Parameters) and are governed by current BOP policy.

- Tuberculosis (TB):
  - **Symptom screening** for TB disease should be considered a public health priority and should be conducted universally, by a trained health care provider, for all newly incarcerated inmates.
  - **Tuberculin skin testing** should be performed on all inmates within 48 hours of intake, except for those with documentation of a prior positive TST (in millimeters), those who have a credible history of being treated for latent TB infection or active TB disease, or

those who report history of a severe reaction to a TST (e.g., swollen, blistering).

• **Chest radiographs** should be performed for inmates with a positive TST. All HIVinfected inmates should have a CXR performed at intake, in addition to their intake TB symptom screen and TST. Routine screening chest radiographs are also now recommended for foreign-born inmates who have been in the United States for one year or less and have no documentation of a chest radiograph obtained in the U.S. This screening guideline also applies to inmates who have been out of the U.S. or Canada for six months or more prior to incarceration in the Bureau of Prisons.

In facilities that house inmates with a high incidence of TB, it may be appropriate to conduct routine CXR screening of all inmates entering the prison. Decisions about the use of routine CXR screening should be made in consultation with the Warden and the HSD staff from the Regional and Central Offices.

- Sexually transmitted disease (STD): Screening for STDs is based on age, gender, and patient-specific risk factors (see <u>Appendix 1</u>).
  - **Female inmates:** Syphilis screening should be conducted universally. Chlamydia screening should be conducted for all women less than age 25, and for other women with identified risk factors.
  - **Male inmates**: Syphilis screening should be provided if the inmate reports risk factors for syphilis. However, Clinical Directors should consider universal syphilis screening for males if the inmate population is drawn from communities where syphilis is hyperendemic, e.g., certain large urban areas.
- **Immunizations:** Immunizations ordinarily are not recommended at the time of intake, except for the measles-mumps-rubella (MMR) vaccine for all women of child-bearing age who report that they have never received the vaccine as an adult.

#### **Prevention Baseline Visit**

A prevention baseline visit should be conducted for all sentenced inmates within six months of incarceration. At the discretion of the Clinical Director and Health Services Administrator, the prevention baseline visit may be either incorporated into the intake physical examination or scheduled later as a separate visit.

The primary purpose of the prevention baseline visit is to assess the inmate's risk factors and identify the need for and frequency of recommended preventive health measures, as outlined in <u>Appendix 2</u> (Preventive Health Care Scope of Services) and <u>Appendix 3</u> (Preventive Health Care Guidelines by Disease State). All inmates should be advised of the preventive health measures that are provided by the BOP, as well as their responsibility for seeking these services. A plan should be developed with the inmate for accessing recommended preventive health services.

The following preventive measures should be provided in accordance with the specific indications outlined in <u>Appendix 2</u>:

• Completing a preventive health risk assessment and developing a plan with the inmate for delivery of follow-up preventive health services.

- Immunizing against tetanus-diphtheria-pertussis, pneumococcal pneumonia, hepatitis A, hepatitis B, measles-mumps-rubella, and influenza (as seasonally appropriate).
- HIV testing should be offered to all sentenced inmates, regardless of risk factor history. HIV testing for sentenced inmates with HIV risk factors is considered mandatory per BOP policy.
- Screening for HBV and HCV infections in asymptomatic inmates is based on the presence of risk factors or upon inmate request.

### **Prevention Periodic Visits**

Periodic visits to review the inmate's need for and receipt of preventive health care services is recommended at least at the following intervals:

- Every three years, for sentenced inmates under age 50 (with the exception of annual tuberculin skin tests, annual influenza vaccinations for certain inmates, and annual audiograms for inmates at occupational risk).
- Annually, for inmates 50 years of age and older.

The frequency of monitoring inmates should be patient-specific, and adjusted as clinically necessary to monitor significant changes in a parameter such as weight or blood pressure.

The following screening parameters should be included in periodic preventive health care visits, as outlined in <u>Appendix 2</u> and <u>Appendix 3</u>:

- Counsel regarding nutrition, exercise, substance abuse, and infectious disease transmission.
- Measure weight and BMI (schedule reevaluation based on trend).
- Measure blood pressure (schedule reevaluation based on trend).
- Screen for latent TB infection with annual tuberculin skin test (unless previously positive).
- Screen for hearing loss with annual audiograms for those at occupational risk.
- Screen for breast, cervical, and colon cancers per established parameters and clinical indications.
- Screen for cardiovascular risk (aspirin need), diabetes, and hypercholesterolemia per criteria.
- Screen for osteoporosis in females 65 years of age and older.
- Screen for abdominal aortic aneurysms in male smokers 65 to 75 years of age.

Universal screening for certain diseases (e.g., glaucoma, ovarian and prostate cancer) is not recommended, due to a lack of evidenced-based data. However, screening for these diseases may be indicated for certain inmates, based on specific risk factors or clinical concerns. Decisions regarding screening for such conditions should be patient-specific.

## 4. Preventive Health Care Delivery

The delivery of preventive health care services is a *shared responsibility between the inmate and the BOP health care team*. Inmates should be provided information on available preventive services, as outlined on the Inmate Fact Sheets (see <u>Appendices 4a</u> and <u>4b</u>), and should be counseled about their responsibility to seek these services. All members of the health care team should take part in preventive health care in some capacity, under the collaborative leadership of the Health Services Administrator and the Clinical Director. Specific assignments are determined locally, based on staffing mix, staff skill sets, and logistical factors. <u>Appendix 5</u> (Staff Roles for *Preventive Health Care Delivery*) outlines how different categories of staff can be utilized in implementing the preventive health program. Additionally, inmate education and preventive services can be delivered, in part, through ancillary means such as group counseling, educational videotapes, and health fairs conducted by volunteers and community-based organizations.

## 5. Preventive Health Care Program Evaluation

Health Services Administrators and Clinical Directors should evaluate their preventive health care programs through their local IOP programs. Applicable evaluation strategies include, but are not limited to:

- Assessing process measures such as the proportion of inmates who were eligible for a certain health screen and were *screened*, e.g., proportion of eligible, female inmates who are screened for breast cancer within the recommended time frames.
- Assessing outcome measures such as the proportion of asymptomatic inmates who were screened for a certain condition and were *diagnosed* with it, e.g., proportion of those screened with a fasting blood glucose who were diagnosed with diabetes.
- **Conducting case studies of inmates who were priority candidates** for preventive services, i.e., inmates who were at high risk for a certain condition, but were not evaluated for the condition.
- Conducting case studies of inmates who were diagnosed clinically, rather than by preventive screening, or who had a negative clinical outcome related to a preventive measure that was not conducted, e.g., an inmate with hypertension who suffered a myocardial infarction and in the process was diagnosed with diabetes (even though the individual should have been a candidate for an earlier diabetes screening).

| All Inmates   |   |  |  |  |  |  |  |
|---|---|--|--|--|--|--|--|
| Detoxification  | Assess need for detoxification at intake health screen.   |  |  |  |  |  |  |
| TB Symptom Screen   | At intake, a health care professional should ask all inmates about a history of tuberculosis and presence of the following symptoms:         - blood tinged sputum         - night sweats         - weight loss         - fever         - cough         Inmates who have symptoms suggestive of TB disease should receive a thorough medical evaluation, including a TST, a chest radiograph, and, if indicated, a sputum examination. If TB is suspected, they should be immediately told to wear a surgical mask and placed in a low traffic area until they can be isolated in an airborne infection isolation (AII) room. |  |  |  |  |  |  |
| Tuberculin Skin Test  | Place TST within 48 hours of intake for all inmates <i>except</i> those with a  |  |  |  |  |  |  |
| (TST)   | credible history of being treated for latent TB infection (TLTBI) or TB disease, or a history of severe reaction to tuberculin. Ignore BCG history. Consider 2-step test for inmates who are foreign-born.  |  |  |  |  |  |  |
| Chest Radiograph  | Obtain intake screening CXR for HIV-infected inmates. Also obtain   |  |  |  |  |  |  |
| (CXR)   | screening CXR for foreign-born inmates who have been in the United<br>States for one year or less, and for whom there is no documentation of a<br>chest radiograph obtained in the U.S. This screening guideline also<br>applies to inmates who have been out of the U.S. or Canada for six months<br>or more prior to incarceration in the BOP.  |  |  |  |  |  |  |
| Vision  | Visual acuity testing with a Snellen eye chart at the intake physical.  |  |  |  |  |  |  |
| Female Inmates  |   |  |  |  |  |  |  |
| Syphilis  | RPR for all females.  |  |  |  |  |  |  |
| Chlamydia   | <ul> <li>Nucleic acid amplification test (NAAT) from urine or cervical swab for females who fall into <i>any</i> of the following categories:</li> <li>Are age 25 and under.</li> <li>Have HIV infection.</li> <li>Have a history of syphilis, gonorrhea, or chlamydia.</li> </ul>  |  |  |  |  |  |  |
| Cervical Cancer   | PAP smear at intake physical. (Use an extended tip spatula to sample the ectocervix and a cytobrush for the endocervix.)  |  |  |  |  |  |  |
| MMR Vaccine         Measles-mumps-rubella (MMR) vaccine at intake for all child women who report never having received MMR as an adult. |   |  |  |  |  |  |  |
| Male Inmates  |   |  |  |  |  |  |  |
| Syphilis*   | <ul> <li>RPR for all males who fall into <i>any</i> of the following categories:</li> <li>Have had sex with another man.</li> <li>Are HIV infected.</li> <li>Have a history of syphilis, gonorrhea, or chlamydia.</li> </ul>  |  |  |  |  |  |  |
| * Consider universal syphi  | lis screening for male inmates from endemic areas.  |  |  |  |  |  |  |

## **Appendix 1. Preventive Health Care – Intake Parameters**

### Appendix 2. Federal Bureau of Prisons—Preventive Health Care Scope of Services for Sentenced Inmates (page 1 of 2)

This chart provides an overview of preventive health services to be offered to *sentenced* inmates, based on age, sex, and identified risk factors. This chart does not include intake preventive health measures (see <u>Appendix 1</u>). An asterisk (\*) in this table indicates that more detail on risk factors and specific screening tests can be obtained from <u>Appendix 3</u>. These guidelines do not cover testing indicated by clinical signs and symptoms; nor do they preclude patient-specific screening based on medical history and evaluation.

| Screening                         | Recommended Age Groups  |                          |        |        |                   |      |        |                             | Tests/Schedule/Risk Factors   |
|-----------------------------------|---|--------------------------|--------|--------|-------------------|------|--------|-----------------------------|---|
| Screening                         |   |                          |        |        | 55                | 60   | 65 70  | Tests/Senedule/Misk Factors |   |
| Prevention<br>Visit               | Eve   | ry 3 years               |        |        |                   | Eve  | ery ye | ar                          | <ul> <li>Prevention Baseline Visit: Within 6 months of intake,</li> <li>Periodic Prevention Visit: Under age 50, every 3 years; Age 50+, annually. Review risk factors and needed screening tests; provide inmate counseling; obtain blood pressure and weight. Calculate BMI: <a href="http://www.cdc.gov/nccdphp/dnpa/bmi/calc-bmi.htm">www.cdc.gov/nccdphp/dnpa/bmi/calc-bmi.htm</a>.</li> <li>If BMI is 30 kg/m<sup>2</sup> or greater: provide nutrition/exercise counseling.</li> </ul> |
| Hepatitis B<br>Viral<br>Infection |   | Ri                       | k-fact | tor ba | sed               |      |        |                             | <b>HBsAg. Risk-factor based*:</b> Ever injected illegal drugs, received tattoos or body piercings while in jail, history of STD, males who have had sex with males, HIV or HCV infection, from high-risk country, on chronic hemodialysis, etc.   |
| Hepatitis C<br>Viral<br>Infection |   | Ri                       | k-fact | tor ba | sed               |      |        |                             | <b>Anti-HCV. Risk-factor based*:</b> Ever injected illegal drugs, received tattoos or body piercings while in jail, HIV or HBV infection, blood transfusion (before 1992), ever on hemodialysis, etc.   |
| HIV<br>Infection                  | Offer HIV testing to all sentenced inmates. HIV testing is mandatory for sentenced inmates with HIV risk factors. |                          |        |        |                   |      |        |                             | <b>HIV EIA. Risk Factors*:</b> Injected illegal drugs, unprotected sex w/ multiple partners or w/ persons at risk for HIV, males who have sex w/ males, history of STD, from Sub-Saharan/W. Africa, hemophiliac, received blood products (1977-85), etc.  |
| ТВ                                |   | Annual tub<br>hest x-ray |        |        | `                 |      | ·      |                             | <b>Annual TST</b> unless documented prior TST(+). <b>CXRs</b> (see <u>Appendix 3</u> for detail):<br><b>Baseline CXR only:</b> If TST (+). <b>Semi-annual CXR indefinitely:</b> If HIV (+) and<br>either TST (+) or a close contact to an active TB case (regardless of TST result)–and<br>have not completed TLTBI. <b>Semi-annual CXR x 2 years:</b> If HIV (-) & TST (+) and<br>either recent TST convertor or close contact of an active TB case and have not<br>completed TLTBI.         |
| Breast<br>Cancer                  |   |                          |        | •      | k: Evo<br>isk: An | •    | •      | 'S                          | <b>Mammogram. Avg Risk:</b> Every 2 years, begin age 40. <b>High Risk:</b> Annually, begin age 40 ("high risk" is defined as at least 2 first-degree relatives w/ breast or ovarian cancer, relative w/ breast cancer before age 50, relative w/ 2 cancers, etc.*)  |
| Cervical<br>Cancer                | Annual  |                          | Eve    | ry 3 y | ears              |      |        |                             | <b>PAP Smear. Age 30 and Younger:</b> Annually. <b>Ages 31–65</b> (if previously normal results): Every 3 years. See <u>Appendix 3</u> for PAP smear procedure.   |
| Colorectal<br>Cancer              | Risk-1  | factor base              | d      |        | An                | nual | FOB    | ST (x3)                     | <b>Fecal Occult Blood Test (3 consecutive) for Average Risk:</b> Annually, begin at age 50. Three tests are required for adequate sensitivity. Stop routine screening at age 75. <b>Higher Risk:</b> Follow American Cancer Society recommendations (see <u>Appendix 3</u> ).   |

| Appendix 2. Federal Bureau of Prisons | —Preventive Health Care Sco | pe of Services for Sentenced Inmates (page 2 of 2) |
|---------------------------------------|-----------------------------|--|
|---------------------------------------|-----------------------------|--|

| Screening                           | 15  | 20   | 25              | 30             | 35        | 40             | 45           | 50               | 55     | 60                                 | 65               | 70   | Tests/Schedule/Risk Factors   |  |  |  |  |
|-------------------------------------|---|--|-----------------|----------------|-----------|----------------|--------------|------------------|--------|------------------------------------|------------------|------|---|--|--|--|--|
| Aspirin for<br>CVD Risk             | ്   |  | <br> <br>       | <br> <br>      | <br> <br> | <br> <br>      | <br>  Ca<br> |                  |        | e 10-year CVD risk<br>very 5 years |                  | risk | Males, ages 45–79:Calculate 10-year CVD risk every 5 years.Risk calculator: <a href="http://healthlink.mcw.edu/article/923521437.html">http://healthlink.mcw.edu/article/923521437.html</a> Females, ages 55–79: Calculate10-year risk of stroke.Risk calculator: <a href="http://www.thecni.org/stroke/risktest.htm">http://www.thecni.org/stroke/risktest.htm</a> |  |  |  |  |
| Factors                             | Ŷ   |  | <br> <br>       | <br> <br> <br> | <br> <br> | <br> <br> <br> | <br> <br>    | <br> <br>        |        |                                    | e 10-y<br>sk q 5 |      | Recommend aspirin 81 mg daily if risk exceeds the following:         Men if 10-year CVD risk:       ages 45-59 (≥4%); ages 60-69 (≥9%); ages70-79 (≥12%)         Female if 10-yr stroke risk:       ages 55-59 (≥3%); ages 60-69 (≥8%); ages 70-79(≥11%)  |  |  |  |  |
| Diabetes<br>(Type II)               |   |  | Hig             | gh risl        | k (BP     | >135           | /80):        | Ever             | y 3 ye | ears                               |                  |      | <b>Fasting Serum Glucose. High Risk:</b> Screen every 3 years if blood pressure is >135/80 (treated or untreated).  |  |  |  |  |
| Hearing                             |   | If oc  | ecupa           | tiona          | l risk    | : Bas          | eline        | & an             | nual   |                                    |                  | nual | Occupational Risk: Annual audiogram. Age 65+: Ask about hearing annually.   |  |  |  |  |
| Lipid<br>Disorders                  | ്   |  | sk-fao<br>based |                | <br> <br> | Ave            | erage        | risk:            | every  | 5 ye                               | ars              |      | If DM, CVD or PVD: Beginning at age 20, perform lipoprotein analysis annually.<br>If other risk factors (relative with CVD disease-male under age 50, or female under   |  |  |  |  |
|                                     | ę   | <br> <br>  |                 | Aver           | 0         |                |              | outine screening |        |                                    |                  |      | age 60; or multiple CVD risk factors, e.g., tobacco & hypertension): Beginning at age 20, screen every 5 years (total chol & HDL). <b>Avg-Risk Males:</b> Beginning at age 35, screen every 5 years (total chol & HDL). <b>Avg-Risk Females:</b> No routine screening.  |  |  |  |  |
| Substance<br>Abuse                  |   | Risk-factor basedscreen every 5 years (total chol & HDL).Avg-Risk Females: No routine screening.Risk-factor basedAssessment of Substance Abuse History (including tobacco). Provide substance<br>abuse counseling and referral as needed.  |                 |                |           |                |              |                  |        |                                    |                  |      |   |  |  |  |  |
| Vaccines                            |   | Vaccine/Indications  |                 |                |           |                |              |                  |        |                                    |                  |      |   |  |  |  |  |
| Tetanus-<br>Diptheria-<br>Pertussis | Tdaj  | <b>Booster-every 10 years.</b> If age <65: Administer a one-time Tdap dose to replace single Td dose (if last Td was $\geq$ 10 years ago). If age $\geq$ 65: Use Td (not Tdap). If incomplete or unknown vaccination history: Administer 3-dose series, including a one-time dose of Tdap (preferably as the initial dose) and 2 doses of Td. For wound management, see BOP guideline on Medical Management of Exposures. For issues related to pregnancy see <u>Appendix 3</u> .  |                 |                |           |                |              |                  |        |                                    |                  |      |   |  |  |  |  |
| Influenza                           |   |  |                 |                |           | -              |              |                  | -      |                                    |                  |      | an wanagement of Exposures. Tor issues related to pregnancy see <u>Appendix 5</u> .   |  |  |  |  |
| Pneumococcal                        | Age<br>(incl<br>dise  | Age 50 or Older or if Risk Factors (see <u>Appendix 3</u> for list)         Age 65 or Older: Administer once.* Risk-Factor Based*: Administer once regardless of age for certain chronic medical conditions such as chronic lung disease (including asthma), chronic CVD, immunocompromising conditions, chemotherapy or long-term systemic corticosteroids, diabetes mellitus, chronic liver diseases, cirrhosis, chronic renal failure or nephrotic syndrome, functional or anatomic asplenia, cochlear implants, CSF leaks, chronic alcoholism, or in long term care. For certain risk factors: Repeat in 5 years (see <u>Appendix 3</u> ). |                 |                |           |                |              |                  |        |                                    |                  |      |   |  |  |  |  |
| Hepatitis A                         |   |  |                 |                |           |                |              |                  |        |                                    |                  | -    | on illegal drugs, liver disease or cirrhosis, recipients of clotting factor concentrates.   |  |  |  |  |
| Hepatitis B                         | <b>Risk-Factor Based*:</b> Certain clinical conditions, including cirrhosis or liver disease, HIV infection (with HBV risk factors), HCV infection (prioritized for those with evidence of liver disease), injection drug use, men who have sex with men, recent history of an STD, inmate workers at risk for bloodborne pathogen exposure, hemodialysis patients, end-stage renal disease, post-exposure prophylaxis, contacts to inmates with acute hepatitis. |  |                 |                |           |                |              |                  |        |                                    |                  |      |   |  |  |  |  |
| MMR                                 |   |  |                 |                |           |                |              | •                |        |                                    |                  |      | Administer 1 dose. Women of childbearing age without evidence of immunity are high  |  |  |  |  |
| * See Annondin 2                    |   |  |                 |                |           |                |              |                  |        |                                    |                  |      | history & if born after 1956: Administer 2-dose series.<br>e, Anti-HCV=HCV antibody, BMI=body mass index, chol=cholesterol,   |  |  |  |  |
|                                     |   |  | -               |                |           |                |              |                  |        |                                    |                  |      | V=hepatitis B virus, $HBsAg$ =hepatitis B surface antigen, $HCV$ =hepatitis C virus,  |  |  |  |  |
|                                     |   |  |                 |                |           |                |              |                  |        |                                    |                  |      |   |  |  |  |  |

## Appendix 3. Preventive Health Care Guidelines by Disease State

Throughout most of this chart, recommendations regarding health screenings and vaccinations are displayed in the third column. These recommendations are based on age, sex, and the risk factors that are listed in the middle column. The first column indicates: the disease or condition, whether the recommendation applies to *all* inmates or only those who are *sentenced* (unless modified in the middle column), and the source of the recommendation.

**Source Abbreviations:** ACS=American Cancer Society, ACIP=Advisory Committee on Immunization Practices, ADA=American Diabetes Association, BOP=Bureau of Prisons, CDC=Centers for Disease Control and Prevention, CDC-DQ=CDC Division of Global Migration and Quarantine, USPSTF=United States Preventive Services Task Force, AGA = American Gastroenterological Association

| Infectious Disease Screening   |  |  |  |
|--|--|--|--|
| Disease/<br>Source   | <b>Risk Factors Indicating Screening</b>   | Screening Test/<br>Guideline   |  |
| Hepatitis B<br>Viral Infection<br>Sentenced<br>BOP, CDC                  | <ul> <li>ever injected illegal drugs and shared equipment</li> <li>received tattoos or body piercings while in jail or prison</li> <li>males who have had sex with another man</li> <li>history of chlamydia, gonorrhea, or syphilis</li> <li>HIV infected</li> <li>HCV infected</li> <li>from high risk country in Africa, Eastern Europe, Western Pacific, or Asia (except Japan)</li> <li>history of percutaneous exposure to blood</li> <li>on chronic hemodialysis and failed to develop antibodies after 2 series of vaccinations (screen monthly) (all)</li> <li>pregnancy (all)</li> </ul> | HBsAg<br>At Baseline Prevention<br>Visit: If HBV risk<br>factors are identified,<br>HBsAg testing is<br>recommended. If inmate<br>is pregnant,<br>test for HBsAg<br>immediately.   |  |
| Hepatitis C<br>Viral<br>Infection<br><i>Sentenced</i><br><i>BOP, CDC</i> | <ul> <li>ever injected illegal drugs and shared equipment</li> <li>received tattoos or body piercings while in jail or prison</li> <li>HIV infected</li> <li>HBV infected (chronic)</li> <li>received blood transfusion/organ transplant before 1992</li> <li>received clotting factor transfusion prior to 1987</li> <li>percutaneous exposure to blood (all)</li> <li>ever on hemodialysis (if currently, screen semiannually)</li> </ul>  | Anti-HCV<br>At Baseline Prevention<br>Visit: If HCV risk<br>factors are identified,<br>recommend testing for<br>anti-HCV.  |  |
| HIV-1<br>Sentenced<br>BOP<br>Federal Law                                 | <ul> <li>HIV risk factors:</li> <li>ever injected illegal drugs and shared equipment</li> <li>males who have had sex with another man</li> <li>had unprotected intercourse with a person with known or suspected HIV infection or multiple sexual partners</li> <li>history of chlamydia, gonorrhea, or syphilis</li> <li>from a high risk country (in Sub-Saharan or West Africa)</li> <li>hemophiliac or received blood products (1977-1985)</li> <li>percutaneous exposure to blood (all)</li> <li>diagnosis of active TB (all)</li> <li>pregnancy (all)</li> </ul>                             | HIV-1 EIA<br>Routinely encourage<br>HIV testing for all<br>sentenced inmates who<br>have not been previously<br>tested in the BOP.<br>HIV testing of sentenced<br>inmates with HIV risk<br>factors is considered<br>mandatory per BOP<br>policy. |  |

#### **Infectious Disease Screening**

| Disease/<br>Source   | <b>Risk Factors Indicating Screening</b>   | Screening Test/<br>Guideline   |
|--|--|--|
| HIV-2<br>Sentenced<br>CDC  | <ul> <li>from the following African countries where HIV-2<br/>prevalence is &gt;1%: Cape Verde, Côte d'Ivoire, Gambia,<br/>Guinea-Bissau, Mali, Mauritania, Nigeria, and Sierra Leone;<br/>from other West African countries reporting HIV-2:<br/>Benin, Burkina Faso, Ghana, Guinea, Liberia, Niger, Sao<br/>Tome, Senegal, and Togo; or from other African nations<br/>reporting HIV-2 at &gt;1%: Angola &amp; Mozambique</li> </ul> | <b>HIV-2 EIA</b><br>For inmates with these<br>risk factors, also test for<br>HIV-2.  |
|  | <ul> <li>have been sex partners or needle-sharing partners of a person from West Africa or a person known to have HIV-2 infection</li> <li>received transfusions in West Africa</li> </ul>   |  |
| Sexually<br>Transmitted<br>Diseases<br>(Chlamydia &<br>Syphilis)<br><i>All</i><br><i>BOP, USPSTF</i> | <ul> <li>All females</li></ul>   | <ul> <li>RPR: at intake physical</li> <li>Chlamydia: at intake physical (NAAT urine or cervical swab)</li> <li>RPR: at intake physical</li> </ul>      |
|  | <i>Note:</i> Routine gonorrhea screening is <i>not</i> recommended unless symptoms of gonorrhea are present, or unless syphilis or chlamydia have been diagnosed.  |  |
| Tuberculosis<br><i>All</i><br>CDC, BOP   | <ul> <li>All inmates</li></ul>   | <ul> <li>Intake TB symptom<br/>screen</li> <li>Tuberculin skin test<br/>(TST) within 48 hrs<br/>of intake</li> <li>Consider 2-step TST</li> </ul>      |
|  | <ul> <li>Foreign born living in U.S. less than 1 year &amp; no history of CXR in U.S.; or U.S. born and has lived outside of U.S. or Canada for the previous 6 months</li> <li>HIV seropositive</li></ul>  | <ul> <li>CXR: At intake</li> <li>CXR: At intake</li> <li>CXR: Every 6 mos indefinitely</li> <li>TST: Annually</li> <li>CXR: Every 6 mos for</li> </ul> |
|  | <ul> <li>Documented HIV (-) TST convertor refusing TLTBI</li> </ul>  | • CXR: Every 6 mos for 2 yrs   |

| Cancer Screen<br>Disease/<br>Source                       | Risk Factors Indicating Scr  | Screening Test/<br>Guideline   |  |
|---|--|--|--|
| Breast Cancer<br>Sentenced<br>BOP, USPSTF,<br>ACA         | <ul> <li>All females</li> <li>Average-risk females, beginning age 40.</li> <li>Risk-factor based, beginning age 40:</li> <li>2 first-degree relatives with breast or or</li> <li>relative with breast cancer before age 5</li> <li>relative with two cancers (breast and or<br/>independent breast cancers)</li> <li>female with male relative with breast cancers)</li> <li>female with male relative with breast cancer</li> <li>The USPSTF recommends that women whose fam<br/>deleterious mutations in <i>BRCA1</i> or <i>BRCA2</i> genes be<br/>for <i>BRCA</i> testing. Certain women of Jewish herita<br/>paternal family histories are important. See USPS'<br/>http://www.ahrq.gov/clinic/uspstf05/brcagen/brcag</li> </ul> | counseling and evaluation<br>d risk. Both maternal and   |  |
| Cervical<br>Cancer<br><i>Sentenced</i><br><i>BOP, ACS</i> | <ul> <li>All females (who have a cervix):</li> <li>Age 30 and younger</li> <li>Ages 31–65 &amp; previously negative PAP so (Use an extended tip spatula to sample the eccytobrush for the endocervix.)</li> </ul>  | <ul> <li>PAP Smear</li> <li>At intake physical,<br/>then annually until 31</li> <li>At intake physical,<br/>then every 3 years</li> </ul>  |  |
| Ovarian<br>Cancer<br><sup>USPSTF</sup>                    | The United States Preventive Services Task Force <i>recommends against routine screening for ovarian cancer</i> , finding that there is no evidence that any screening test (including CA-125, ultrasound, or pelvic examination) reduces mortality from ovarian cancer.   |  |  |
| Prostate<br>Cancer<br><i>USPSTF</i>                       | The United States Preventive Services Task Force has <i>found insufficient evidence to</i><br><i>recommend for or against routine screening for prostate cancer</i> by prostate surface antiger<br>or digital rectal exam. Decisions about screening should be made case-by-case, with the<br>inmate. Prostate cancer screening should not be done for men over age 75.  |  |  |
| Disease/<br>Source  | <b>Risk Factors Indicating Screening</b>   | Screening Test/Guideline   |  |
| Colorectal<br>Cancer<br>Sentenced<br>USPSTF, ACS.<br>AGA  | <ul> <li>Average risk</li> <li>Increased risk: Follow guidance on <i>next</i> page if:</li> <li>history of polyps at prior colonoscopy</li> <li>history of colorectal cancer</li> <li>family history</li> <li>genetic predisposition</li> <li>inflammatory bowel disease</li> </ul>  | <ul> <li>Fecal occult blood test, annually beginning at age 50. Stop routine screening at age 75. Provide guiac-based test cards to use with 3 consecutive stools and return to clinic. Do not rehydrate specimen. If positive do colonoscopy.</li> <li>Note: It is necessary to test 3 stools each year to achieve adequate sensitivity.</li> </ul> |  |

## **Colorectal Screening Guidelines:** Increased and High Risk

#### Guidelines for Screening and Surveillance for the Early Detection of Colorectal Adenomas and Cancer in Individuals at Increased Risk or High Risk (AGA/ACS, 2008)

| <b>Risk Category</b>  | Age to Begin   | <b>Recommendation/Comment</b>  |  |  |
|---|--|--|--|--|
| Increased Risk: Patients with History of Polyps at Prior Colonoscopy  |  |  |  |  |
| Patients with small rectal<br>hyperplastic polyps   | Same as those with average risk  | <i>Colonoscopy or other screening options</i> at same<br>regular intervals as for those at average risk. Those<br>with hyperplastic polyposis syndrome are at<br>increased risk for adenomatous polyps and cancer,<br>and should have more intensive follow-up.  |  |  |
| People with 1 or 2 small<br>(<1 cm) tubular<br>adenomas with low-grade<br>dysplasia   | 5–10 years after the polyps are removed  | <i>Colonoscopy.</i> Time between tests should be based<br>on other factors such as prior colonoscopy findings,<br>family history, and patient and doctor preferences.  |  |  |
| People with 3 to 10<br>adenomas, or a large ( $\geq$ 1<br>cm) adenoma, or any<br>adenomas with<br>high-grade dysplasia or<br>villous features | 3 years after the polyps<br>are removed  | <i>Colonoscopy.</i> Adenomas must have been<br>completely removed. If colonoscopy is normal or<br>shows only 1 or 2 small tubular adenomas with<br>low-grade dysplasia, future colonoscopies can be<br>done every 5 years.   |  |  |
| People with more than 10<br>adenomas on a single<br>exam  | Within 3 years after the polyps are removed  | <i>Colonoscopy.</i> Consider possibility of genetic syndrome (such as FAP or HNPCC).   |  |  |
| Patients with sessile<br>adenomas that are<br>removed in pieces   | 2–6 months after adenoma removal   | <i>Colonoscopy.</i> If entire adenoma has been removed, further testing should be based on physician's judgment.   |  |  |
| Increased Risk: Patien  | ts with Colorectal Cancer  |  |  |  |
| People diagnosed with colon or rectal cancer  | At time of colorectal<br>surgery, or can be 3–6<br>months later if person<br>doesn't have cancer spread<br>that can't be removed   | <i>Colonoscopy</i> to view entire colon and remove all polyps. If the tumor presses on the colon/rectum and prevents colonoscopy, CT colonoscopy (with IV contrast) or DCBE may be done to look at the rest of the colon.  |  |  |
| People who have had<br>colon or rectal cancer<br>removed by surgery   | Within 1 year after cancer<br>resection (or 1 year after<br>colonoscopy to make sure<br>the rest of the<br>colon/rectum was clear) | <i>Colonoscopy.</i> If normal, repeat exam in 3 years. If<br>normal then, repeat exam every 5 years. Time<br>between tests may be shorter if polyps are found or<br>there is reason to suspect HNPCC. After low<br>anterior resection for rectal cancer, exams of the<br>rectum may be done every 3–6 months for the first<br>2–3 years to look for signs of recurrence. |  |  |
|   | continued or   | n next page  |  |  |

| <b>Risk Category</b>  | Age to Begin   | <b>Recommendation/Comment</b>  |
|---|--|--|
| Increased Risk: Patien  | ts with a Family History   |  |
| Colorectal cancer or<br>adenomatous polyps in<br>any first-degree relative<br>before age 60, or in 2 or<br>more first-degree<br>relatives at any age (if<br>not a hereditary<br>syndrome) | Age 40, or 10 years before<br>the youngest case in the<br>immediate family,<br>whichever is earlier  | Colonoscopy. Every 5 years.  |
| Colorectal cancer or<br>adenomatous polyps in<br>any first-degree relative<br>aged 60 or higher, or in<br>at least 2 second-degree<br>relatives at any age                                | Age 40   | Fecal occult blood test x 3 annually.  |
| High Risk   |  |  |
| Familial adenomatous<br>polyposis (FAP)<br>diagnosed by genetic<br>testing, or suspected FAP<br>without genetic testing   | Age 10 to 12   | <i>Yearly flexible sigmoidoscopy</i> to look for signs of FAP. Provide counseling to consider genetic testing if it hasn't been done. If genetic test is positive, removal of colon (colectomy) should be considered.  |
| Hereditary non-polyposis<br>colon cancer (HNPCC),<br>or increased risk of<br>HNPCC based on family<br>history without genetic<br>testing  | Age 20 to 25, or 10 years<br>before the youngest case<br>in the immediate family   | <i>Colonoscopy</i> every 1–2 years; counseling to<br>consider genetic testing if it hasn't been done.<br>Genetic testing should be offered to first-degree<br>relatives of people found by genetic tests to have<br>HNPCC mutations. It should also be offered if 1 of<br>the first 3 of the modified Bethesda criteria <sup>1</sup> is met. |
| <ul> <li>Inflammatory bowel<br/>disease:</li> <li>Chronic ulcerative<br/>colitis</li> <li>Crohn's disease</li> </ul>  | Cancer risk begins to be<br>significant 8 years after<br>the onset of pancolitis<br>(involvement of entire<br>large intestine), or 12–15<br>years after the onset of<br>left-sided colitis | <i>Colonoscopy</i> every 1–2 years with biopsies for dysplasia. These patients are best referred to a center with experience in the surveillance and management of inflammatory bowel disease.   |
|   | uble-contrast barium enema; FAP<br>yposis colon cancer; CTC = com  | = familial adenomatous polyposis;<br>puted tomographic colonoscopy,  |
|   | -  | "Can Colorectal Cancer Be Prevented?" available at:<br><u>n and rectum cancer be prevented.asp?sitearea=</u>   |
| colorectal polyps and cancer be f   | ound early? Revised 3/5/2008. Ava  | etailed guide: colon and rectum cancer. Can<br>ilable from:<br>a and rectum cancer be found early.asp  |

| Chronic Diseases/ Lifestyle                         |  |  |  |
|---|--|--|--|
| Disease/<br>Source                                  | <b>Risk Factors Indicating Screening</b>   | Screening Test/<br>Guideline   |  |
| Abdominal<br>Aortic<br>Aneurysm<br><i>Sentenced</i> | At risk: Men, ages 65–75, with a history of smoking.Screen for abdominal aortic aneurysm (AAA); surgically<br>repair large AAAs (5.5 cm or more).                          | Abdominal<br>Ultrasonography<br>once   |  |
| USPSTF  |  |  |  |
| Aspirin for<br>CHD &                                | Males ages 45–79: Calculate CHD risk every 5 years using risk calculator:<br>http://healthlink.mcw.edu/article/923521437.html  |  |  |
| Stroke Risk   | Females ages 55-79: Calculate risk of stroke every 5 yea<br>http://www.thecni.org/stroke/risktest.htm  | ars using stroke calculator:   |  |
| Sentenced   | If risk of adverse cardiovascular event exceeds risk of gas<br>recommend that inmate take aspirin 81 mg every day.   | strointestinal bleed, then   |  |
| USPSTF  | Risk Level at which CVD Events Prevented ("Benefit") H   | Exceeds GI Harms:  |  |
|   |  | 7 <b>omen: 10-Year Stroke Risk</b><br>ges 55–59 ≥3%                              |  |
|   |  | ges 60–69 >8%  |  |
|   |  | ges 70–79 $\geq 11\%$  |  |
| Diabetes<br>Mellitus<br>Sentenced                   | <b>Risk-factor based:</b> If blood pressure is >135/80 or if otherwise clinically indicated.   | <b>Fasting Serum Glucose</b><br>every 3 years.                                   |  |
| ADA, BOP,<br>USPSTF                                 | The BOP recommends the use of serum glucose testing for initial fasting serum glucose values are borderline high a fasting plasm   |  |  |
| Hypertension  | Based on age:  | Blood Pressure   |  |
| Sentenced   | ► Under age 50   | · ·  |  |
| BOP/USPSTF  | <ul> <li>Age 50 and over</li> <li>Borderline blood pressure elevations</li> <li>(avetalia 120, 120) diastalia 80,00)</li> </ul>  | <ul><li>At least annually</li><li>At least annually</li></ul>                    |  |
|   | (systolic 120-139; diastolic 80-90)  |  |  |
| Lipids<br>Sentenced                                 | • If diabetes, CVD or peripheral vascular disease,<br>beginning at age 20  | Fasting<br>Lipoproteinanalysis<br>. ▶ annually                                   |  |
| USPSTF  | <ul> <li>If risk factors: first-degree relative with CVD (male before age 50, female before age 60) or tobacco use and hypertension, <i>beginning at age 20</i></li> </ul> | <ul> <li>Total Cholesterol &amp; HDL</li> <li>at least every 5 years.</li> </ul> |  |
|   | <ul> <li>Average risk men: Beginning at age 35</li> </ul>  | 5 5  |  |
|   | Average risk women:      If lipid levels are close to warranting therapy, then shorten   | <ul> <li>screening not indicated a<br/>any age</li> </ul>                        |  |

| Disease/<br>Source  | <b>Risk Factors Indicating Screening</b>  | Screening Test/<br>Guideline   |
|---|---|--|
| Obesity<br>Sentenced<br>USPSTF                                    | Calculate Body Mass Index (BMI), utilizing calculator at<br><u>www.cdc.gov/nccdphp/dnpa/bmi/calc-bmi.htm</u><br>• Under age 50<br>• Age 50 and older  | Height/ Weight/<br>Body Mass Index<br>• every 3 years<br>• every year  |
| Osteoporosis<br>Sentenced<br>USPSTF,<br>Surgeon<br>General Report | <ul> <li>Women age 65 and older</li> <li>Risk factor based: women age 60–64 with body weight less than 70 kilograms and no current use of estrogen.</li> <li>Repeat screening as clinically indicated.</li> </ul>           | Bone Density<br>Screening<br>The most commonly<br>recommended test is<br>dual x-ray<br>absorptiometry (DXA). |
| Substance<br>Abuse<br><i>BOP</i>                                  | <ul> <li>All inmates: At intake assess for substance abuse history<br/>and need for detoxification. Provide counseling and referral<br/>to BOP substance abuse and smoking cessation programs,<br/>as indicated.</li> </ul> | Substance Abuse<br>History at intake   |
| Sensory Scree   | ning  |  |
| Vision<br>Sentenced<br>USPSTF                                     | <ul> <li>All inmates</li></ul>  | <ul> <li>Snellen at intake physical</li> <li>Snellen annually</li> </ul>                                     |
| Hearing<br>Sentenced<br>USPSTF/BOP                                | <ul> <li>Age 65 and older</li> <li>Occupational risk (any age)</li> </ul>   | <ul> <li>Ask about hearing<br/>annually</li> <li>Audiogram<br/>annually</li> </ul>                           |

#### Immunizations

For more specific information about immunizations and contraindications, see: CDC adult immunization recommendations: <u>http://www.cdc.gov/vaccines/recs/schedules/adult-schedule.htm</u>. For information about pregnant women, refer to the current adult immunization schedule (see link above).

| Vaccine/<br>Source                         | Risk Factor   | Guideline  |
|--|---|--|
| Hepatitis A<br>Sentenced<br>CDC, BOP, ACIP | <ul> <li>Risk-factor based:</li> <li>men who have sex with men</li> <li>users of injection illegal drugs</li> <li>liver disease or cirrhosis</li> <li>recipients of clotting factor concentrates</li> </ul> For foreign born inmates consider prescreening for hepatitis A immunity prior to vaccination.   | At Baseline Prevention Visit: If<br>patient has risk factors for hepatitis A,<br>start two-dose series; administer 2 <sup>nd</sup><br>dose at least 6 months after 1 <sup>st</sup> dose.<br>The two available single antigen<br>vaccines (Vaqta® and Havrix®) can be<br>used interchangeably.<br>For candidates for both vaccines, the<br>combined hepatitis A and hepatitis B<br>vaccine (Twinrix®) can be used.<br>Administer 3 doses at 0, 1, and 6<br>months; or alternatively, use a 4-dose<br>schedule, administered on days 0, 7 and<br>21–30, followed by a booster dose at<br>month 12. |
| Hepatitis B<br>Sentenced<br>BOP, CDC, ACIP | <ul> <li>Risk-factor based:</li> <li>hemodialysis patients</li> <li>end-stage renal disease (hemodialysis anticipated)</li> <li>inmate workers at risk for bloodborne pathogen exposure</li> <li>HIV infected (with risk factors for acquiring HBV)</li> <li>HCV infection (prioritized for those with evidence of liver disease)</li> <li>cirrhosis or liver disease</li> <li>injection drug use</li> <li>men who have sex with men</li> <li>history of syphilis, gonorrhea, or chlamydia in last 6 months</li> <li>post-exposure prophylaxis</li> <li>contacts to inmates consider prescreening for hepatitis B immunity prior to vaccination.</li> </ul> | At Prevention Baseline Visit: If<br>patient has risk factors for hepatitis B,<br>start three-dose series. The 2 <sup>nd</sup> dose is<br>given 1–2 months after the 1 <sup>st</sup> dose.<br>The 3 <sup>rd</sup> dose is given 4–6 weeks after<br>the 2 <sup>nd</sup> dose (or thereafter).<br>For candidates for both vaccines, the<br>combined hepatitis A and hepatitis B<br>vaccine (Twinrix®) can be used.<br>Administer 3 doses at 0, 1, and 6<br>months; or alternatively, use a 4-dose<br>schedule, administered on days 0, 7 and<br>21–30, followed by a booster dose at<br>month 12.   |

| Vaccine/<br>Source  | <b>Risk Factor</b>  | Guideline  |
|---|---|--|
| Influenza<br>All<br>ACIP, CDC                                 | <ul> <li>Age 50 or older</li> <li>Medical risk factors         <ul> <li>Chronic disorders of the cardiovascular or pulmonary systems, including asthma</li> <li>Chronic metabolic diseases, including diabetes mellitus, renal or hepatic dysfunction, hemoglobinopathies</li> <li>Immunocompromising conditions, including HIV</li> <li>Asplenia, including sickle cell disease</li> <li>Any condition that compromises respiratory function, e.g., cognitive dysfunction, spinal cord injury, or seizure disorder</li> <li>Pregnancy (during flu season)</li> </ul> </li> <li>Occupational/Residential risk factors:         <ul> <li>inmate health care workers</li> <li>residents of long term care facilities</li> </ul> </li> </ul> | Annually. Inmates age 50 and older,<br>and those who are younger with risk<br>factors should receive annual influenza<br>vaccine.  |
| Measles-<br>Mumps-<br>Rubella<br>(MMR)<br><i>ACIP, CDC-DQ</i> | <ul> <li>Women of child-bearing age (All)</li> <li>If born after 1956 and previously vaccinated (Sentenced)</li> <li>If incomplete or unknown vaccination history and born after 1956 (Sentenced)</li> </ul>  | <ul> <li>At Intake: Administer 1 dose.</li> <li>At Prevention Baseline Visit:<br/>Administer 1 booster dose.</li> <li>At Prevention Baseline Visit:<br/>Administer initial dose of two-dose<br/>series; then give 2nd dose 4–8<br/>weeks later.</li> </ul> |
| Meningococcal<br>All  | <i>Notes:</i><br>(1) HIV infection is not a contraindication to MM<br>immunocompromised, i.e., CD4+ T-cell count <<br>(2) MMR is <i>contraindicated</i> during pregnancy.<br>Anatomic or functional asplenia, including<br>sickle cell disease ( <i>age 55 and under only</i> )   |  |
| ACIP, CDC   |   |  |

| Vaccine/<br>Source  | Risk Factor  |  | Guideline   |
|---|--|--|---|
| Pneumococcal<br>Sentenced<br>ACIP   | <ul> <li>Age 65 and over</li></ul>   | asthma)<br>s<br>s<br>tic<br>a (e.g.,<br>omy)*<br>ons (e.g.,<br>HIV<br>a, multiple<br>eneralized<br>atation)*<br>agents,  | <ul> <li>Administer once*</li> <li>Administer once, regardless of age.<br/>For patients who are age 65 or older,<br/>administer a one-time re-vaccination<br/>if the person was vaccinated 5 years<br/>or more ago, and was less than age<br/>65 when initially vaccinated.</li> <li>* For inmates with asterisked<br/>conditions, give one-time<br/>revaccination after 5 years.</li> <li>Notes: <ol> <li>Administer pneumococcal vaccine as<br/>soon as possible after HIV-infection is<br/>diagnosed.</li> <li>Routine use of pneumococcal vaccine is<br/>no longer recommended for Alaska Native<br/>or American Indian persons younger than<br/>65 years unless they have other qualifying<br/>medical conditions.</li> <li>Pneumococcal vaccine can be<br/>administered to pregnant women with risk<br/>factors.</li> </ol> </li> </ul> |
| Tetanus-<br>Diphtheria-<br>Pertussis<br><i>Sentenced</i><br><i>ACIP, CDC-DQ</i> | <ul> <li>If previously vaccinated and<br/>last dose of Td ≥ 10 years ago</li> <li>If incomplete or unknown<br/>vaccination history</li> </ul>  | <ul> <li>To protect against pertussis, a one-time Tdap dose should replace a single dose of Td for adults ages 19 through 64 years, who have not received a dose of Tdap previously (either as a booster dose or part of a vaccine series).</li> <li>At Prevention Baseline Visit: <ul> <li>If Age &lt;65: Administer one-time Tdap dose to replace a single Td dose.</li> <li>If Age ≥65: Administer Td (not Tdap).</li> </ul> </li> <li>At Prevention Baseline Visit: Administer 3-dose tetanus-diphtheria-pertussis series, including a one-time dose of Tdap (preferably as the initial dose) and 2 doses of Td. Administer first 2 doses at least 4 weeks apart and the 3<sup>rd</sup> dose 6–12 months after the 2<sup>nd</sup> dose.</li> </ul> |   |
|   | <i>Note:</i> Pregnant women in need of vaccine may receive Td in the 2 <sup>nd</sup> or 3 <sup>rd</sup> trimester. Do not administer Tdap during pregnancy. To protect against pertussis, administer a one-time Tdap dose during the immediate post-partum period (even if less than 10 years have passed since the last Td dose). |  |   |

#### **Appendix 4a. Inmate Fact Sheet – Preventive Health Program for Women**

#### Initial Preventive Health Screening

| You will receive th   | ne following preventive health screening shortly after you enter federal prison:  |
|-----------------------|---|
| TB Skin Test          | <ul> <li>To test for exposure to TB, unless your medical record shows a previous<br/>positive TB skin test.</li> </ul>  |
| Chest X-Ray           | <ul> <li>If you have a positive TB skin test, if you are foreign-born or have recently<br/>been outside the U.S., or you have HIV infection.</li> </ul>                 |
| Chlamydia Test        | <ul> <li>If you are age 25 or less, have HIV infection, or have a history of sexually<br/>transmitted diseases such as syphilis, gonorrhea, or chlamydia.</li> </ul>    |
| Syphilis Test         | <ul> <li>At your intake physical exam.</li> </ul>   |
| PAP Smear             | • To test for cervical cancer or other conditions, at your intake physical exam.  |
| MMR Vaccine           | <ul> <li>To protect against measles, mumps, and rubella; given if you are of child-<br/>bearing age and have no record of vaccination.</li> </ul>                       |
| Your health care pr   | rovider may recommend additional health screens (tests) based on your medical   |
| history and physica   | al examination.   |
| <b>Routine Prever</b> | ntive Health Screening for Sentenced Inmates  |
| The following prev    | ventive health tests are routinely provided for <i>sentenced</i> inmates:   |
| Viral Hepatitis       | • If you are at risk for hepatitis B or hepatitis C viral infections, or if you report that you had a prior infection.  |
| HIV                   | <ul> <li>Recommended for all sentenced inmates.</li> </ul>  |
| TB Skin Test          | <ul> <li>Every year, unless your record shows a positive test in the past.</li> </ul>   |
| Breast Cancer         | <ul> <li>Mammogram every 2 years, beginning at age 40; annually, if there is a history<br/>of breast cancer in your family. Annual breast exam upon request.</li> </ul> |
| Pap Smear             | <ul> <li>Every year, if you are age 30 or younger.</li> </ul>   |
|                       | <ul> <li>Every 3 years, if you are over age 30.</li> </ul>  |
| Colon Cancer          | <ul> <li>Testing for blood in your stool every year, beginning at age 50;<br/>colonoscopy if you are at higher risk for colon cancer.</li> </ul>                        |
| Diabetes              | <ul> <li>If your blood pressure is greater than 135/80.</li> </ul>  |
| Cholesterol           | <ul> <li>Beginning at age 20, but only if you have risk factors.</li> </ul>   |
| In addition vaccin    | ations are provided as recommanded by health authorities. Based on your age and   |

In addition, vaccinations are provided as recommended by health authorities. Based on your age and specific needs, other preventive health services may be made available to you. You can also request a *preventive health visit* to review needed services: every three years (if you are under age 50) or every year (if you are age 50 and over).

#### Take care of yourself while you are in prison!

- Exercise regularly.
- Eat a healthy diet (low fat, more fruits and vegetables).
- Take medications as recommended by your doctor. Don't use tobacco or illegal drugs.
- Don't have sexual contact with others while in prison.
- Don't get a tattoo while in prison.
- Don't share personal items (razors, toothbrushes, towels).
- Wash your hands regularly.

## Appendix 4b. Inmate Fact Sheet – Preventive Health Program for Men

#### Initial Preventive Health Screening

|  | ive meanen bereenning  |
|--|--|
| You will receive the                     | he following preventive health screening shortly after you enter federal prison:   |
| TB Skin Test                             | <ul> <li>To test for exposure to TB, unless your medical record shows a previous<br/>positive TB skin test.</li> </ul>   |
| Chest X-Ray                              | <ul> <li>If you have a positive TB skin test, if you are foreign-born or have recently<br/>been outside the U.S., or if you have HIV infection.</li> </ul>   |
| Syphilis Test                            | <ul> <li>At your intake physical exam if you have HIV infection, or if you have a<br/>history of sexually transmitted diseases such as syphilis, gonorrhea, or<br/>chlamydia.</li> </ul>   |
| Your health care p<br>history and physic | rovider may recommend additional health screens (tests) based on your medical al examination.  |
| Routine Preve                            | ntive Health Screening for Sentenced Inmates   |
| The following pre-                       | ventive health tests are routinely provided for <i>sentenced</i> inmates:  |
| Viral Hepatitis                          | • If you are at risk for hepatitis B or hepatitis C viral infections, or if you report that you had a prior infection.   |
| HIV                                      | <ul> <li>Recommended for all sentenced inmates.</li> </ul>   |
| TB Skin Test                             | • Every year, unless you had a positive test in the past.  |
| Colon Cancer                             | • Testing for blood in your stool every year, beginning at age 50; colonoscopy if you are at higher risk for colon cancer.   |
| Diabetes                                 | <ul> <li>If your blood pressure is greater than 135/80.</li> </ul>   |
| Cholesterol                              | • Beginning at age 35, screen every 5 years (sooner if you are at risk).   |
| specific needs, oth                      | nations are provided as recommended by health authorities. Based on your age and<br>her preventive health services may be made available to you. You can also request a<br><i>visit</i> to review needed services: every three years (if you are under age 50) or every<br>the 50 and over). |
| Take care of yo                          | ourself while you are in prison!   |
|  |  |

- Exercise regularly.
- Eat a healthy diet (low fat, more fruits and vegetables).
- Take medications as recommended by your doctor.
- Don't use tobacco or illegal drugs.
- Don't have sexual contact with others while in prison.
- Don't get a tattoo while in prison.
- Don't share personal items (razors, toothbrushes, towels).
- Wash your hands regularly.

## Appendix 5. Staff Roles for Preventive Health Care Delivery

**Primary Care Provider Teams** will be responsible for providing preventive health care services in each facility. Roles and responsibilities for specific aspects of preventive health care will vary, based on staffing in each facility and adaptations required to maintain clinic operations. The most efficient and cost-effective way to implement the preventive health care guidelines is to assign appropriate responsibilities to each health care professional team member. All team members should be oriented to the guidelines in this document.

#### **Clerical Staff**

Possible tasks include pulling and filing medical records, scheduling appointments, preparing lab slips, and auditing records.

#### **Nursing Staff**

Emphasis on preventive health care may involve an expanded role for nurses in each facility, depending on their availability.

**Preparation for Preventive Health Visits:** In advance of the visit, a thorough chart review should be conducted to determine what tests and evaluations are indicated by the inmate's age, sex, and risk factors. Laboratory tests and evaluations can be ordered prior to the visit (utilizing standing orders), to maximize clinic efficiency.

**Preventive Health Visits:** Nursing functions can include interviewing inmates, assessing risk factors, recommending and ordering (with standing orders) specific health screens and interventions, instructing inmates about prevention measures, administering immunizations, and providing health education.

**Preventive Health Follow-Up:** Abnormal results shall be reviewed and referred to the MLP or physician for follow-up.

#### **Mid-Level Practitioners**

MLPs are responsible for: ensuring that their patients have been offered preventive services; counseling inmates on serious health conditions that require treatment; following-up on abnormal results; and developing a treatment plan.

#### Physicians

Physicians are responsible for developing a treatment plan—particularly for complicated patients—and for mentoring and advising MLPs on specific patients.

#### **Clinical Director**

The Clinical Director is responsible for serving as a role model and leader in delivering preventive health services; providing standing orders for nurses; providing staff education; developing IOP measures; and working with the Health Services Administrator to ensure that adequate staffing, supplies, and materials are available for successful implementation of the program.

### Appendix 6. Selected Preventive Health Care References

U.S. Preventive Services Task Force (USPSTF). Topic Index: A–Z. Available from: <u>http://www.ahrq.gov/clinic/uspstf/uspstopics.htm</u>. A PDA program is available, the *Electronic Preventive Services Selector*. To download, go to <u>http://pda.ahrq.gov</u>. More detailed publications of the USPSTF are referenced below under the relevant topic.

#### A. Physical Examinations – Historic Reference

American Medical Association, Council on Scientific Affairs. Medical evaluations of healthy persons. *JAMA*. 1983;249:1626–1633.

#### **B.** Behavioral Counseling

U.S. Preventive Services Task Force. Behavioral counseling in primary care to promote a healthy diet: recommendations and rationale. *Am J Prev Med.* 2003;24(1):93–00. Available from: http://www.ahrq.gov/clinic/3rduspstf/diet/dietrr.pdf

U.S. Preventive Services Task Force. *Behavioral counseling in primary care to promote physical activity: recommendations and rationale.* Rockville, MD: Agency for Healthcare Research and Quality; 2002. Available from: http://www.ahrq.gov/clinic/3rduspstf/physactivity/physactrr.htm

U.S. Preventive Services Task Force. *Counseling to prevent tobacco use and tobacco-related diseases: recommendation statement.* Rockville, MD: Agency for

Healthcare Research and Quality; 2003. Available from: http://www.ahrq.gov/clinic/3rduspstf/tobacccoun/tobcounrs.htm

#### C. Infectious Disease Screening

#### Hepatitis (Viral)

Centers for Disease Control and Prevention. Prevention and control of infections with hepatitis viruses in correctional settings. *MMWR*. 2003;52(RR01):1–33. Available from:

http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5201a1.htm

U.S. Preventive Services Task Force. *Screening for Hepatitis B infection: recommendation statement*. Rockville, MD: Agency for Healthcare Research and Quality; 2004. Available from: http://www.ahrq.gov/clinic/3rduspstf/hepbscr/hepbrs.htm

U.S. Preventive Services Task Force. Screening for hepatitis C in adults: recommendation statement. *Ann Intern Med.* 2004;140:462–464. Available from: http://www.ahrq.gov/clinic/3rduspstf/hepcscr/hepcrs.pdf

#### HIV

Centers for Disease Control and Prevention [homepage on the Internet]. *HIV/AIDS*. Accessed April 14. 2009. Available from: <u>http://www.cdc.gov/hiv/</u>

Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. *MMWR*. 2006;55(RR14):1–17. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm

Federal Bureau of Prisons. *Clinical practice guidelines: medical management of HIV infection*. Federal Bureau of Prisons, Washington, DC: Federal Bureau of Prisons; 2006. Available from: <a href="http://www.bop.gov/news/medresources.jsp">http://www.bop.gov/news/medresources.jsp</a>

#### Sexually Transmitted Diseases

Centers for Disease Control and Prevention (2005). *Program and operations guide for STD prevention: medical and laboratory services*. Available from: <u>http://www.cdc.gov/std/program/med&lab.pdf</u>

Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2006. *MMWR*. 2006;55(RR-11). Available from: <u>http://www.cdc.gov/std/treatment/</u>

Federal Bureau of Prisons. *Clinical practice guidelines: STD treatment tables.* Federal Bureau of Prisons, Washington, DC: Federal Bureau of Prisons; 2008. <u>http://www.bop.gov/news/medresources.jsp</u>

#### Tuberculosis

American Thoracic Society and Centers for Disease Control and Prevention. Treatment of tuberculosis. *MMWR*. 2003; 52(RR11):1–77. Available from: http://www.cdc.gov/MMWR/preview/MMWRhtml/rr5211a1.htm

Centers for Disease Control and Prevention. Prevention and control of tuberculosis in correctional and detention facilities: recommendations from CDC. *MMWR*. 2006;55(No. RR-09). Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5509a1.htm

Federal Bureau of Prisons. *Clinical practice guidelines: management of tuberculosis*. Federal Bureau of Prisons, Washington, DC: Federal Bureau of Prisons; 2007. Available from: http://www.bop.gov/news/medresources.jsp

#### **D.** Cancer Screening

American Cancer Society [homepage on the internet]. *American Cancer Society Guidelines for the Early Detection of Cancer*. Revised 3/5/2008. Accessed April 14. 2009. Available from: http://www.cancer.org/docroot/ped/content/ped 2 3x acs cancer detection guidelines 36.asp

#### **Breast Cancer**

American Cancer Society [homepage on the internet]. *Detailed Guide: Breast Cancer. Can Breast Cancer Be Found Early?* Revised 9/4/2008. Accessed April 14. 2009. Available from: http://www.cancer.org/docroot/CRI/content/CRI 2 4 3X Can breast cancer be found early 5.asp

U.S. Preventive Services Task Force. *Screening for breast cancer*. Rockville, MD: Agency for Healthcare Research and Quality; 2002. Available from: <u>http://www.ahrq.gov/clinic/uspstf/uspsbrca.htm</u>

U.S. Preventive Services Task Force. *Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility*. Rockville, MD: Agency for Healthcare Research and Quality; 2005. Available from: <u>http://www.ahrq.gov/clinic/uspstf/uspsbrgen.htm</u>

#### **Cervical Cancer**

U.S. Preventive Services Task Force. *Screening for cervical cancer: recommendations and rationale*. Rockville, MD: Agency for Healthcare Research and Quality; 2003. Available from: <u>http://www.ahrq.gov/clinic/3rduspstf/cervcan/cervcanrr.htm</u>

#### **Colorectal Cancer**

American Cancer Society [homepage on the Internet]. *Detailed guide: colon and rectum cancer. Can colorectal polyps and cancer be found early?* Revised 3/5/2008. Accessed April 14. 2009. Available from:http://www.cancer.org/docroot/CRI/content/CRI 2 4 3X Can colon and rectum cancer be foun d\_early.asp?sitearea=

U.S. Preventive Services Task Force. *Screening for colorectal cancer*. Rockville, MD: Agency for Healthcare Research and Quality; 2008. Available from: http://www.ahrq.gov/CLINIC/USPSTF/uspscolo.htm

#### **Ovarian Cancer**

U.S. Preventive Services Task Force. *Screening for ovarian cancer*. Rockville, MD: Agency for Healthcare Research and Quality; 2004. Available from: http://www.ahrq.gov/Clinic/uspstf/uspsovar.htm U.S. Preventive Services Task Force. *Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility*. Rockville, MD: Agency for Healthcare Research and Quality; 2005. Available from: <u>http://www.ahrq.gov/CLINIC/USPSTF/uspsbrgen.htm</u>

#### **Prostate Cancer**

U.S. Preventive Services Task Force. *Screening for prostate cancer*. Rockville, MD: Agency for Healthcare Research and Quality; 2008. Available from: <u>http://www.ahrq.gov/CLINIC/USPSTF/uspsprca.htm</u>

#### E. Chronic Disease Screening and Prevention

#### Abdominal Aortic Aneurysm

U.S. Preventive Services Task Force. *Screening for abdominal aortic aneurysm*. Rockville, MD: Agency for Healthcare Research and Quality; 2005. Available from: http://www.ahrq.gov/clinic/uspstf05/aaascr/aaars.htm

#### Cardiovascular Risk: Aspirin for Primary Prevention

U.S. Preventive Services Task Force. *Aspirin for the prevention of cardiovascular disease*. Rockville, MD: Agency for Healthcare Research and Quality; 2009. Available from: http://www.ahrq.gov/clinic/USpstf/uspsasmi.htm

CVD 10-year risk calculator: <u>http://healthlink.mcw.edu/article/923521437.html</u> Stroke 10-year risk calculator: <u>http://www.thecni.org/stroke/risktest.htm</u>

#### Diabetes

U.S. Preventive Services Task Force. *Screening for type 2 diabetes mellitus in adults*. Rockville, MD: Agency for Healthcare Research and Quality; 2008. Available from: http://www.ahrq.gov/CLINIC/USPSTF/uspsdiab.htm

Federal Bureau of Prisons. *Clinical practice guidelines for management of diabetes*. Federal Bureau of Prisons, Washington, DC: Federal Bureau of Prisons; 2009. Available from: http://www.bop.gov/news/medresources.jsp

#### Hypertension

Federal Bureau of Prisons. *Clinical practice guidelines for hypertension*. Federal Bureau of Prisons, Washington, DC: Federal Bureau of Prisons; 2004. Available from: http://www.bop.gov/news/medresources.jsp U.S. Preventive Services Task Force. *Screening for high blood pressure*. Rockville, MD: Agency for Healthcare Research and Quality; 2007. Available from: http://www.ahrq.gov/CLINIC/USPSTF/uspshype.htm

#### Lipids

Federal Bureau of Prisons. *Clinical practice guidelines: management of lipid disorders*. Federal Bureau of Prisons, Washington, DC: Federal Bureau of Prisons; 2006. Available from: <u>http://www.bop.gov/news/medresources.jsp</u>

U.S. Preventive Services Task Force. *Screening for lipid disorders*. Rockville, MD: Agency for Healthcare Research and Quality; 2008. Available from: <a href="http://www.ahrq.gov/CLINIC/uspstf/uspschol.htm">http://www.ahrq.gov/CLINIC/uspstf/uspschol.htm</a>

#### Obesity

Centers for Disease Control and Prevention [homepage on the Internet]. *Body Mass Index Calculator*. Accessed April 20, 2009. Available from: <u>http://www.cdc.gov/nccdphp/dnpa/bmi/calc-bmi.htm</u>

U.S. Preventive Services Task Force. *Screening for obesity in adults*. Rockville, MD: Agency for Healthcare Research and Quality; 2003. Available from: <u>http://www.ahrq.gov/clinic/uspstf/uspsobes.htm</u>

#### Osteoporosis

Raisz LG. Clinical practice. Screening for osteoporosis. N Engl J Med. 2005;353:164–171.

U.S. Department of Health and Human Services. *Bone Health and Osteoporosis: A Report of the Surgeon General*. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General, 2004. Available from: <u>http://www.surgeongeneral.gov/library/reports.htm</u>

U.S. Preventive Services Task Force. *Screening for Osteoporosis in Postmenopausal Women: Recommendations and Rationale.* Rockville, MD: Agency for Healthcare Research and Quality, September 2002. Available from: <u>http://www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm</u>

#### F. Immunizations

Centers for Disease Control and Prevention. Division of Global Migration and Quarantine [homepage on the Internet]. *Technical Instructions to Panel Physicians*. Revised October 29, 2008. Accessed April 20, 2009. Available from: http://www.cdc.gov/ncidod/dq/panel.htm

Centers for Disease Control and Prevention [homepage on the internet]. *Adult Immunization Schedule*. Accessed April 20, 2009. Available from: http://www.cdc.gov/vaccines/recs/schedules/adult-schedule.htm.